The Ebola epidemic: Is there a way out?
International Union of Immunology Societies calls for rapid and adequate funding of trials on experimental vaccines and therapies
2014-10-27
(Press-News.org) Berlin, 27 October 2014. Not everyone who contracts the Ebola virus dies, the survival rate is around 30% suggesting that some kind of immunity to the disease is possible. Experimental treatments and vaccines against Ebola exist but have not yet been tested in large groups for safety and efficacy (phase 2 trials).
The International Union of Immunology Societies (IUIS) published a statement today in its official journal, Frontiers in Immunology calling for urgent and adequate funding of vaccine candidates in clinical trials and speedy implementation of immunisation in African countries.
"The current Ebola outbreak, is an unprecedented disaster for humans. This virus cunningly hijacks the human immune system with devastating effects. Without blocking transmission, Ebola may become endemic," says Prof Clive Gray, author of the paper and member of the Clinical Immunology Committee of the IUIS, from the Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, South Africa. "Efforts are being made on health communication in order to prevent the spread of this virus from person to person. This is essential but not enough. Stakeholders need to work together to accelerate the roll out of vaccines and therapies," Gray stated.
According to the IUIS paper, vaccination will be a vital additional strategy. Authors explain that although no licensed vaccines exist on the market, "significant progress" has been made in recent years and especially in the last few months. Among the promising vaccines being tried today, the paper mentions the Cad3 Ebola vaccine developed using chimpanzee adenovirus. This vaccine was found to protect animals with a single dose and is currently undergoing phase 1 trials (where researchers test the vaccine candidate in a small group of people to evaluate safety, determine safe dosage and identify side effects). Another promising vaccine candidate is rVSV-ΔG-ZEBOV that has proven safe and efficient in non-human primates with no major toxicities. Phase 1 trials for this vaccine started in October.
Commenting on the need for a vaccination strategy, Prof Marylyn Addo, Department of Medicine, Division of Emerging Infections and Tropical Medicine, University Medical Centre, Hamburg, Germany explained: "the fact that the current outbreak of Ebola is through a single strain with low mutability, suggests that vaccine strategies could be easily achievable. Understanding how immunity works in survivors of Ebola may further contribute to strategic vaccine design and optimisation. » Addo concluded that: « we need to speed up the development process in order to advance clinical testing and, ultimately, the deployment of effective vaccines. However, despite the urgency of the situation, the safety of the vaccines for recipients needs to be ensured and cannot be compromised."
Alongside vaccination (to prevent infection), the IUIS paper says that experimental therapies are also available to treat people who are already infected with the virus. ZMapp, for example, combines antibodies that cling to the virus and allow the immune system to clear it. The drug has been tried on animals and humans with different outcomes. Currently the drug is not available, so it cannot be tested further.
Other therapeutic approaches are siRNA (also known as TKM-Ebola) and Favipiravir (T705). "These drugs need to be tried for efficacy and safety, but currently we do not have time to conduct traditional studies," explained Prof Reinhold Schmidt, Director of the Centre of Internal Medicine, Division of Immunology and Rheumatology, University of Hannover, Germany.
The IUIS paper calls for a speedy roll-out of a human vaccine to Ebola. Prof Schmidt continues, "Of course we do not overrule the need for trials to ensure safety, but IUIS is calling on authorities to speed up the process by a) performing parallel animal safety and immunogenicity studies alongside human phase 1 clinical trials with small sets of volunteers to assess safety and optimal dosage and b) rapidly designing and implementing phase 2 clinical trials." Prof Schmidt concluded: "Time is not on our side. Funding is urgently needed, as well as a more flexible and speedy process to make vaccines available to populations at greatest risk, in order to halt this devastating Ebola outbreak."
INFORMATION:
ELSE PRESS RELEASES FROM THIS DATE:
2014-10-27
A new study has found that patients who received chest radiation for Wilms tumor, a rare childhood cancer, face an increased risk of developing breast cancer later in life due to their radiation exposure. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings suggest that cancer screening guidelines might be re-evaluated to facilitate the early diagnosis and prompt treatment of breast cancer among Wilms tumor survivors.
Wilms tumor is a rare childhood kidney cancer that can spread to the lungs. When this spread occurs, patients ...
2014-10-27
Today, the International Osteoporosis Foundation (IOF) has published an educational slide deck highlighting 60 original scientific abstracts presented at the Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in September 2014.
The succinct slide kit can be downloaded free of charge by all individual IOF members (free sign up on the IOF website).
CEO Judy Stenmark stated, "IOF is pleased to provide this informative resource for healthcare professionals interested in the latest advances in bone and mineral research. While 10% of the featured ...
2014-10-27
Toronto, Canada – Making mistakes while learning can benefit memory and lead to the correct answer, but only if the guesses are close-but-no-cigar, according to new research findings from Baycrest Health Sciences.
"Making random guesses does not appear to benefit later memory for the right answer , but near-miss guesses act as stepping stones for retrieval of the correct information – and this benefit is seen in younger and older adults," says lead investigator Andrée-Ann Cyr, a graduate student with Baycrest's Rotman Research Institute and the Department ...
2014-10-27
VANCOUVER ─ Different ethnic groups have widely varying differences in both the prevalence and awareness of cardiovascular risk factors, a finding that highlights the need for specially designed education and intervention programs, according to a study presented today at the 2014 Canadian Cardiovascular Congress.
The conclusion comes from a study of more than 3,000 patients at an urgent-care clinic serving an ethnically diverse area of Toronto. Participants were asked to self-identify their ethnicity and, from a list of 20 activities or conditions, asked to identify ...
2014-10-27
VANCOUVER ─ People facing mental health challenges are significantly more likely to have heart disease or stroke, according to a study presented today at the Canadian Cardiovascular Congress.
"This population is at high risk, and it's even greater for people with multiple mental health issues," says Dr. Katie Goldie, lead author of the study and a postdoctoral fellow at the Centre for Addiction and Mental Health in Toronto
Using data from the Canadian Community Health Survey, Dr. Goldie explored the associations between cardiovascular risk and disease, mental ...
2014-10-27
VANCOUVER ─ Heart surgery patients who received newly donated blood have significantly fewer post-operative complications than those who received blood that had been donated more than two weeks before their surgery, a study presented at the Canadian Cardiovascular Congress has shown.
The study examined records at the New Brunswick Heart Centre (NBHC) in Saint John for non-emergency heart surgeries performed over almost nine years, from January 2005 to September 2013, on patients who received red blood cells either during their surgery or afterwards and who stayed ...
2014-10-27
This news release is available in French.
In less than a minute, a miniature device developed at the University of Montreal can measure a patient's blood for methotrexate, a commonly used but potentially toxic cancer drug. Just as accurate and ten times less expensive than equipment currently used in hospitals, this nanoscale device has an optical system that can rapidly gauge the optimal dose of methotrexate a patient needs, while minimizing the drug's adverse effects. The research was led by Jean-François Masson and Joelle Pelletier of the university's Department ...
2014-10-26
In an analysis that included approximately 35,000 participants, genetic predisposition to elevated low-density lipoprotein cholesterol (LDL-C) was associated with aortic valve calcium and narrowing of the aortic valve, findings that support a causal association between LDL-C and aortic valve disease, according to a study appearing in JAMA. The study is being released to coincide with its presentation at the Canadian Cardiovascular Congress.
Aortic valve disease remains the most common form of heart valve disease in Europe and North America and is the most common indication ...
2014-10-26
Stanford, CA— Proteins are the machinery that accomplishes almost every task in every cell in every living organism. The instructions for how to build each protein are written into a cell's DNA. But once the proteins are constructed, they must be shipped off to the proper place to perform their jobs. New work from a team of scientists led by Carnegie's Munevver Aksoy and Arthur Grossman, describes a potentially new pathway for targeting newly manufactured proteins to the correct location. Their work is published by The Plant Cell.
The team's discovery concerns ...
2014-10-26
October 26, 2014, New York, NY – Ludwig Oxford researchers have discovered a key mechanism that governs how cells of the epithelia, the soft lining of inner body cavities, shift between a rigid, highly structured and immobile state and a flexible and motile form. Published in the current issue of Nature Cell Biology, their study shows that a tumor suppressor protein named ASPP2 functions as a molecular switch that controls this process and its reverse, both of which play a critical role in a number of biological phenomena, including wound healing, embryonic development ...
LAST 30 PRESS RELEASES:
[Press-News.org] The Ebola epidemic: Is there a way out?
International Union of Immunology Societies calls for rapid and adequate funding of trials on experimental vaccines and therapies
